We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

88 hedge funds and large institutions have $118M invested in BioXcel Therapeutics in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 37 increasing their positions, 21 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 21

14% more call options, than puts

Call options by funds: $6.79M | Put options by funds: $5.96M

0.04% more ownership

Funds ownership: 3.75% → 3.79% (+0.04%)

8% less funds holding

Funds holding: 96 → 88 (-8)

38% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 21

64% less capital invested

Capital invested by funds: $325M → $118M (-$207M)

Holders
88
Holders Change
-8
Holders Change %
-8.33%
% of All Funds
1.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
37
Reduced
21
Closed
21
Calls
$6.79M
Puts
$5.96M
Net Calls
+$833K
Net Calls Change
-$1.29M

Top Buyers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
+$7.27M
2
State Street
State Street
Massachusetts
+$6.48M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$5.4M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$5.04M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$3.93M

Top Sellers

Rank Fund Capital Flow
1
DCM
Driehaus Capital Management
Illinois
-$7.63M
2
Two Sigma Investments
Two Sigma Investments
New York
-$4.07M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$2.73M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$2.69M
5
IC
Ikarian Capital
Texas
-$2.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
WTA
76
Washington Trust Advisors
Massachusetts
$8.32K – – –
AAG
77
Armstrong Advisory Group
Massachusetts
$7.99K +$4K +12 +19%
MLICM
78
Metropolitan Life Insurance Company (MetLife)
New York
$6.76K – – –
Fifth Third Bancorp
79
Fifth Third Bancorp
Ohio
$6.66K – – –
Canada Life
80
Canada Life
Manitoba, Canada
$5K – – –
National Bank of Canada
81
National Bank of Canada
Quebec, Canada
$3.77K – – –
Carson Wealth (CWM LLC)
82
Carson Wealth (CWM LLC)
Nebraska
$1K -$333 -1 -17%
SWM
83
Spire Wealth Management
Virginia
$872 – – –
FDCDDQ
84
Federation des caisses Desjardins du Quebec
Quebec, Canada
$753 – – –
VCM
85
Versant Capital Management
Arizona
$173 +$666 +2 New
LC
86
Lindbrook Capital
California
$147 – – –
Nisa Investment Advisors
87
Nisa Investment Advisors
Missouri
$93 – – –
Two Sigma Investments
88
Two Sigma Investments
New York
– -$4.07M -13,624 Closed
IC
89
Ikarian Capital
Texas
– -$2.48M -8,313 Closed
Renaissance Technologies
90
Renaissance Technologies
New York
– -$1.75M -5,875 Closed
Federated Hermes
91
Federated Hermes
Pennsylvania
– -$1.15M -3,858 Closed
Two Sigma Advisers
92
Two Sigma Advisers
New York
– -$1.07M -3,588 Closed
AA
93
AlphaCentric Advisors
Puerto Rico
– -$746K -2,500 Closed
Voloridge Investment Management
94
Voloridge Investment Management
Florida
– -$645K -2,160 Closed
BFM
95
Boothbay Fund Management
New York
– -$504K -1,688 Closed
AA
96
ALPS Advisors
Colorado
– -$344K -1,154 Closed
TRSOTSOK
97
Teachers Retirement System of the State of Kentucky
Kentucky
– -$326K -1,093 Closed
Verition Fund Management
98
Verition Fund Management
Connecticut
– -$249K -832 Closed
PAM
99
PVG Asset Management
Colorado
– -$224K -750 Closed
ECM
100
Endurant Capital Management
California
– -$242K -728 Closed
1 2 3
4
5

BTAI Hedge Fund Activity: Q2 2023 in Review

88 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2023, worth a combined $118M — down 64% from $325M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of BTAI and 13 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 37 added.

The largest buyer was Ameriprise, opening a new position worth an estimated $7.27M. The largest seller was Driehaus Capital Management, cutting an estimated $7.63M.

  • 88 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2023, down from 96 in Q1 2023.
  • Funds reported $118M of BioXcel Therapeutics stock for Q2 2023, down 64% quarter-over-quarter.
  • 13 funds opened new BioXcel Therapeutics positions in Q2 2023 and 21 closed out, a net change of -8 holders.
  • The largest BioXcel Therapeutics buyer in Q2 2023 was Ameriprise, an estimated $7.27M added.
  • The largest BioXcel Therapeutics seller in Q2 2023 was Driehaus Capital Management, an estimated $7.63M sold.

Based on aggregated 13F filings for Q2 2023.